Arzerra (ofatumumab) is approved for patients with chronic lymphocytic leukemia (CLL) whose cancer is no longer being controlled by other forms of chemotherapy. The product was approved under the FDA's accelerated approval process, which allows earlier approval of drugs that meet unmet medical needs.
Sign in with your MM&M account
Keep me signed in Forgot your password?
I would like to receive relevant information via email from MM&M.
Enter your MM&M registration email address to receive a password reset link.
ENTER NEW PASSWORD
It looks like we already have a MM&M account for:
Please confirm the information BELOW to link this account to your account
I would like to receive relevant information via email from Haymarket Media
Not you? Create an account for free »